As reported by Reuters on 20-Dec-09, the amendments to the US healthcare bill will exclude the clause that caused IMS shareholders headache over the last couple of weeks and saw the share price dip below the USD 19 level on 11-Dec-09:  
"A closely watched proposal that took aim at the use of doctors' prescribing habits for marketing purposes was excluded."
This should reduce any uncertainty stemming from the healthcare bill jitters surrounding the IMS take-over and reduce the IMS spread to the $22 cash take over price. We remain buyers under the $21 level, assuming completion in Feb-10.